Den europeiske union -
norsk -
EMA (European Medicines Agency)
sunitinib accord
accord healthcare s.l.u. - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastiske midler - gastrointestinal stromal tumour (gist)sunitinib accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sunitinib accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sunitinib accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pnet) with disease progression in adults.
Norge -
norsk -
Statens legemiddelverk
sunitinib newbury 50 mg
newbury pharmaceuticals ab - sunitinibmalat - kapsel, hard - 50 mg
Norge -
norsk -
Statens legemiddelverk
sunitinib newbury 12.5 mg
newbury pharmaceuticals ab - sunitinibmalat - kapsel, hard - 12.5 mg
Norge -
norsk -
Statens legemiddelverk
sunitinib newbury 25 mg
newbury pharmaceuticals ab - sunitinibmalat - kapsel, hard - 25 mg
Norge -
norsk -
Statens legemiddelverk
sunitinib sandoz 12.5 mg
sandoz - københavn - sunitinib - kapsel, hard - 12.5 mg
Norge -
norsk -
Statens legemiddelverk
sunitinib sandoz 25 mg
sandoz - københavn - sunitinib - kapsel, hard - 25 mg
Norge -
norsk -
Statens legemiddelverk
sunitinib sandoz 50 mg
sandoz - københavn - sunitinib - kapsel, hard - 50 mg
Norge -
norsk -
Statens legemiddelverk
sunitinib teva 12.5 mg
teva b.v. - sunitinib - kapsel, hard - 12.5 mg
Norge -
norsk -
Statens legemiddelverk
sunitinib teva 25 mg
teva b.v. - sunitinib - kapsel, hard - 25 mg
Norge -
norsk -
Statens legemiddelverk
sunitinib teva 50 mg
teva b.v. - sunitinib - kapsel, hard - 50 mg